Summary of COVID-19 astodrimer sodium studies

1. Winchester et al., Astodrimer Sodium Nasal Spray versus Placebo in Non-Hospitalised Patients with COVID-19: A Randomised, Double-Blinded, Placebo-Controlled Trial

197 patient astodrimer sodium early treatment RCT: 19% improved recovery (p=0.41) and 24% improved viral clearance (p=0.3).
RCT 222 non-hospitalized low risk COVID-19 patients showing lower SARS-CoV-2 viral load, faster viral clearance, and improvements in symptoms, particularly anosmia, with astodrimer sodium nasal spray compared to placebo. The reduction in viral load and benefits were statistically significant in patients aged 45 years and older, with greater effects in older age groups. There was only one hospitalization event. Treatment delay is not specified and may be relatively late - authors suggest that patients were "already at or past the time of peak viral load, and the infection was already in its decline phase".
Sep 2024, Pharmaceutics, https://www.mdpi.com/1999-4923/16/9/1173, https://c19p.org/winchester2